Abstract
The development of liver diseases in patients suffering from chronic hepatitis B infection is determined by the nature of the host immune response. Several factors have made this immune response difficult to study, but recently developed animal models will help clear the way.
References
Chang, K-M., & Chisari, F.V. Immuno-pathogenesis of hepatitis B virus infection. Clin. Liver Dis. 3, 221–239 (1999).
Chisari, F.V., & Ferrari, C. In: Viral pathogenesis (ed., Nathanson, N.) 745–778 (Lippincot-Raven, Philadelphia, 1997).
Tennant, B.C. Animal models of hepatitis B virus infection. Clin. Liver Dis. 3, 241–266 (1999).
Vickery, K., Cossart, Y., & Dixon R. Cellular immune response of ducks to duck hepatitis B virus infection. J. Med. Virol. 58, 19–25 (1999).
Menne, S., Maschke, J., Lu, M., Grosse-Wilde, H., & Roggendorf, M. T-cell response to woodchuck hepatitis virus (WHV) antigens during acute self-limited WHV infection and convalescence and after viral challenge. J. Virol. 72, 6083–6091 (1998).
Chisari, F.V. Hepatitis B virus transgenic mice: Models of viral immunobiology and pathogenesis. Curr. Top. Microbiol. 206, 150–173 (1996).
Larkin, J. et al. Hepatitis B virus transgenic SCID mouse model of chronic liver disease. Nature Med. 5, 907–912 (1999).
Guidotti, L.G. et al. Intracellular inactivation of the hepatitis B virus by cytotoxic T lymphocytes. Immunity 4, 25–36 (1996).
Guidotti, L.G. et al. Cytotoxic T lymphocytes inhibit hepatitis B virus gene expression by a noncytolytic mechanism in transgenic mice. Proc. Natl. Acad. Sci. USA. 91, 3764–3768 (1994).
Guidotti, L.G. et al. Viral clearance without destruction of infected cells during acute HBV infection. Science 284, 25–29 (1999).
Krogsgaard, K. et al. The treatment effect of alpha interferon in chronic hepatitis B is independent of pre-treatment variables. Results based on individual patient data from 10 clinical controlled trials. European Concerted Action on Viral Hepatitis (Eurohep). J. Hepatol. 21, 646–655 (1994).
Dienstag, J.L. et al. A preliminary trial of lamivudine for chronic hepatitis B infection. N. Engl. J. Med. 333, 1657–1661 (1995).
Pol, S. et al. Immunotherapy of chronic hepatitis B by anti HBV vaccine. Acta. Gastroenterol. Belg. 61, 228–233 (1998).
Heathcote, J. et al. A pilot study of the CY-1899 T-cell vaccine in subjects chronically infected with hepatitis B virus. Hepatology 30, 531–536 (1999).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Menne, S., Tennant, B. Unraveling hepatitis B virus infection of mice and men (and woodchucks and ducks). Nat Med 5, 1125–1126 (1999). https://doi.org/10.1038/13445
Issue Date:
DOI: https://doi.org/10.1038/13445
- Springer Nature America, Inc.
This article is cited by
-
Molecular viral oncology of hepatocellular carcinoma
Oncogene (2003)